Nelarabine is an anticancer chemotherapeutic compound used to treat T-cell malignancies such as acute lymphoblastic leukemia (ALL). Nelarabine is the prodrug of 9-β-D-arabinofuranosylguanine (ara-G), and acts as a nucleoside analog of guanosine, inhibiting DNA synthesis.
| Cas No. | 121032-29-9 |
|---|---|
| Purity | ≥98% |
| Formula | C11H15N5O5 |
| Formula Wt. | 297.26 |
| Chemical Name | (2R,3S,4R,5R)-2-(2-amino-6-methoxy-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol |
| IUPAC Name | (2R,3S,4S, 5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol |
| Synonym | 506U78 |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet |
|---|
Forcade E, Leguay T, Vey N, et al. Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival. Biol Blood Marrow Transplant. 2013 Jul;19(7):1124-6. PMID: 23648236.
Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. PMID: 22591387.
Roecker AM, Stockert A, Kisor DF. Nelarabine in the treatment of refractory T-cell malignancies. Clin Med Insights Oncol. 2010 Dec 1;4:133-41. PMID: 21151585.
Reilly KM, Kisor DF. Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia. Onco Targets Ther. 2009 Feb 18;2:219-28. PMID: 20616909.
Buie LW, Epstein SS, Lindley CM. Nelarabine: a novel purine antimetabolite antineoplastic agent. Clin Ther. 2007 Sep;29(9):1887-99. PMID: 18035189.
